AMAL Therapeutics Raises €8 Million (CHF 8.8 Million) in First Closing of Series B Financing Round
Geneva, Switzerland, 05 September, 2017 – AMAL Therapeutics (AMAL), the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today…